11 February 2021

Wockhardt has been granted a six-month extension to its contract with the UK Government to fill-finish Covid-19 vaccines. This expands the initial agreement from 18 to 24 months, meaning the contract will last until August 2022. Manufacturing is expected to take place at CP Pharmaceuticals, Wockhardt’s subsidiary based in  Wrexham, North Wales.

Indian pharmaceutical company Biological E is looking to contract manufacture approximately 600 million doses of Johnson and Johnson (J&J)’s Covid-19 vaccine each year, according to Reuters. Biological E’s managing director Mahima Datla further stated that it was not clear when the company would start production, but it is also looking to introduce its own Covid-19 product.

Chugai Pharmaceutical announced positive results from its Phase III J-COVACTA clinical study for the humanised anti-human IL-6 receptor monoclonal antibody Actemra Intravenous Infusion to treat  patients with Covid-19 associated pneumonia. Actemra has not been approved by any health authorities, but Chugai will discuss filing with the Japanese health authority based on ongoing studies.